Immature host for xenotransplantation

Robert E. Michler, Oktavijan P. Minanov, John H. Artrip, Silviu Itescu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The overall shortage of appropriate donor organs has prompted transplant physicians and surgeons to consider using organs from other nonhuman species. The shortage of appropriate human donor hearts for newborn recipients is especially severe. Presently, the pig appears to be the most appropriate source for organs. Humans and baboons uniformly develop high titers of complement-fixing (IgM) anti-pig xenoantibodies, resulting in complement- mediated hyperacute rejection (HAR) of pig organs transplanted into mature baboons within minutes to hours. In contrast, newborn humans and baboons do not have high titers of anti-pig IgM xenoantibody, and consequently pig cardiac xenografts transplanted into newborn baboons do not undergo HAR. Rather, these organs are rejected at days 3 to 4 by a distinctive immunologic process that involves natural killer cells and macrophages. With the addition of cyclosporine-based triple immunosuppression, this process is reduced and graft life is prolonged to 6 to 7 days. This therapy, however, is not sufficient to prevent the induced humoral response to the graft, and the organs are rejected by antibody- and complement-dependent mechanisms. Future treatment strategies to reduce this humoral response must incorporate immunodepletion columns, soluble complement-inhibiting agents, and additional anti-B lymphocyte agents. These strategies, in conjunction with the use of transgenic pig organs that express human membrane-bound complement regulatory proteins or reduced xenoantigenic epitopes could further prolong graft life. Clinical trials are being formulated that would utilize pig organs as a 'bridge,' sustaining a newborn human in need of a heart transplant until an appropriate donor is located.

Original languageEnglish (US)
Pages (from-to)924-931
Number of pages8
JournalWorld Journal of Surgery
Volume21
Issue number9
DOIs
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Heterologous Transplantation
Swine
Papio
Transplants
Heterophile Antibodies
Tissue Donors
Complement Inactivating Agents
Newborn Infant
Heterografts
Natural Killer Cells
Immunosuppression
Cyclosporine
Epitopes
Complement System Proteins
B-Lymphocytes
Macrophages
Clinical Trials
Physicians
Membranes
Antibodies

ASJC Scopus subject areas

  • Surgery

Cite this

Immature host for xenotransplantation. / Michler, Robert E.; Minanov, Oktavijan P.; Artrip, John H.; Itescu, Silviu.

In: World Journal of Surgery, Vol. 21, No. 9, 11.1997, p. 924-931.

Research output: Contribution to journalArticle

Michler, RE, Minanov, OP, Artrip, JH & Itescu, S 1997, 'Immature host for xenotransplantation', World Journal of Surgery, vol. 21, no. 9, pp. 924-931. https://doi.org/10.1007/s002689900328
Michler, Robert E. ; Minanov, Oktavijan P. ; Artrip, John H. ; Itescu, Silviu. / Immature host for xenotransplantation. In: World Journal of Surgery. 1997 ; Vol. 21, No. 9. pp. 924-931.
@article{d32da1a7fb714a7c910e1d192fc0c9be,
title = "Immature host for xenotransplantation",
abstract = "The overall shortage of appropriate donor organs has prompted transplant physicians and surgeons to consider using organs from other nonhuman species. The shortage of appropriate human donor hearts for newborn recipients is especially severe. Presently, the pig appears to be the most appropriate source for organs. Humans and baboons uniformly develop high titers of complement-fixing (IgM) anti-pig xenoantibodies, resulting in complement- mediated hyperacute rejection (HAR) of pig organs transplanted into mature baboons within minutes to hours. In contrast, newborn humans and baboons do not have high titers of anti-pig IgM xenoantibody, and consequently pig cardiac xenografts transplanted into newborn baboons do not undergo HAR. Rather, these organs are rejected at days 3 to 4 by a distinctive immunologic process that involves natural killer cells and macrophages. With the addition of cyclosporine-based triple immunosuppression, this process is reduced and graft life is prolonged to 6 to 7 days. This therapy, however, is not sufficient to prevent the induced humoral response to the graft, and the organs are rejected by antibody- and complement-dependent mechanisms. Future treatment strategies to reduce this humoral response must incorporate immunodepletion columns, soluble complement-inhibiting agents, and additional anti-B lymphocyte agents. These strategies, in conjunction with the use of transgenic pig organs that express human membrane-bound complement regulatory proteins or reduced xenoantigenic epitopes could further prolong graft life. Clinical trials are being formulated that would utilize pig organs as a 'bridge,' sustaining a newborn human in need of a heart transplant until an appropriate donor is located.",
author = "Michler, {Robert E.} and Minanov, {Oktavijan P.} and Artrip, {John H.} and Silviu Itescu",
year = "1997",
month = "11",
doi = "10.1007/s002689900328",
language = "English (US)",
volume = "21",
pages = "924--931",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Immature host for xenotransplantation

AU - Michler, Robert E.

AU - Minanov, Oktavijan P.

AU - Artrip, John H.

AU - Itescu, Silviu

PY - 1997/11

Y1 - 1997/11

N2 - The overall shortage of appropriate donor organs has prompted transplant physicians and surgeons to consider using organs from other nonhuman species. The shortage of appropriate human donor hearts for newborn recipients is especially severe. Presently, the pig appears to be the most appropriate source for organs. Humans and baboons uniformly develop high titers of complement-fixing (IgM) anti-pig xenoantibodies, resulting in complement- mediated hyperacute rejection (HAR) of pig organs transplanted into mature baboons within minutes to hours. In contrast, newborn humans and baboons do not have high titers of anti-pig IgM xenoantibody, and consequently pig cardiac xenografts transplanted into newborn baboons do not undergo HAR. Rather, these organs are rejected at days 3 to 4 by a distinctive immunologic process that involves natural killer cells and macrophages. With the addition of cyclosporine-based triple immunosuppression, this process is reduced and graft life is prolonged to 6 to 7 days. This therapy, however, is not sufficient to prevent the induced humoral response to the graft, and the organs are rejected by antibody- and complement-dependent mechanisms. Future treatment strategies to reduce this humoral response must incorporate immunodepletion columns, soluble complement-inhibiting agents, and additional anti-B lymphocyte agents. These strategies, in conjunction with the use of transgenic pig organs that express human membrane-bound complement regulatory proteins or reduced xenoantigenic epitopes could further prolong graft life. Clinical trials are being formulated that would utilize pig organs as a 'bridge,' sustaining a newborn human in need of a heart transplant until an appropriate donor is located.

AB - The overall shortage of appropriate donor organs has prompted transplant physicians and surgeons to consider using organs from other nonhuman species. The shortage of appropriate human donor hearts for newborn recipients is especially severe. Presently, the pig appears to be the most appropriate source for organs. Humans and baboons uniformly develop high titers of complement-fixing (IgM) anti-pig xenoantibodies, resulting in complement- mediated hyperacute rejection (HAR) of pig organs transplanted into mature baboons within minutes to hours. In contrast, newborn humans and baboons do not have high titers of anti-pig IgM xenoantibody, and consequently pig cardiac xenografts transplanted into newborn baboons do not undergo HAR. Rather, these organs are rejected at days 3 to 4 by a distinctive immunologic process that involves natural killer cells and macrophages. With the addition of cyclosporine-based triple immunosuppression, this process is reduced and graft life is prolonged to 6 to 7 days. This therapy, however, is not sufficient to prevent the induced humoral response to the graft, and the organs are rejected by antibody- and complement-dependent mechanisms. Future treatment strategies to reduce this humoral response must incorporate immunodepletion columns, soluble complement-inhibiting agents, and additional anti-B lymphocyte agents. These strategies, in conjunction with the use of transgenic pig organs that express human membrane-bound complement regulatory proteins or reduced xenoantigenic epitopes could further prolong graft life. Clinical trials are being formulated that would utilize pig organs as a 'bridge,' sustaining a newborn human in need of a heart transplant until an appropriate donor is located.

UR - http://www.scopus.com/inward/record.url?scp=0030669356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030669356&partnerID=8YFLogxK

U2 - 10.1007/s002689900328

DO - 10.1007/s002689900328

M3 - Article

VL - 21

SP - 924

EP - 931

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 9

ER -